Clinical trials: Glaucoma,Open-Angle
Primary Open Angle Glaucoma, Ocular Hypertension
ATS907 Ph2a Open-Label Dose-ranging Safety and Tolerability in Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (OHT) Subjects
This single-site, dose-escalation study will evaluate safety and tolerability of increasing concentrations of ATS907 in 12 subjects with Primary Open Angle Glaucoma and/or Ocular Hypertension
- Trial name
- NCT01668524
- Testing
- ATS907
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Altheos, Inc.
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma
Phase III trial involving topical application, in both eyes, of trabodenoson ophthalmic formulation 3.0% or 6.0% once per day or 4.5% twice per day, placebo twice per day, or timolol 0.5% twice per day for 12 weeks in adult…
- Trial name
- MATrX-1 (NCT02565173)
- Testing
- trabodenoson 4.5% BID, trabodenoson 6.0% QD, trabodenoson 3.0% QD
- Where
- United States
- Volunteers
- 303 people
- Sponsor
- Inotek Pharmaceuticals Corporation
Glaucoma, Open-Angle, Glaucoma
iStent Inject New Enrollment Post-Approval Study
Study to evaluate the rate of clinically relevant complications associated with iStent inject placement in the post-market setting.
- Trial name
- NCT04624698
- Testing
- iStent Inject Implantation
- Where
- 3 sites in United States
- Volunteers
- 358 people
- Sponsor
- Glaukos Corporation
Primary Open Angle Glaucoma
The Effects of an Antioxidant Formulation on Ocular Blood Flow
The objective is to evaluate the effects of an antioxidant formula versus placebo on ocular blood flow in a randomized double-blind, crossover design.
- Trial name
- NCT01930487
- Testing
- dietary supplement with antioxidants
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- ScienceBased Health
Open-angle Glaucoma, Ocular Hypertension
DuoTrav® Eye Drops As Replacement Therapy Program
To evaluate the effectiveness of DuoTrav Eye Drops in gaining or maintaining control of target Intraocular Pressures (tIOP) in patients diagnosed with, and being treated for, open-angle glaucoma (OAG) or ocular hypertension (OH).
- Trial name
- NCT00828906
- Testing
- DuoTrav
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Alcon Research
Glaucoma, Open-Angle
An Observational Multicenter Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System In Pseudophakic Eyes With Primary Open Angle Glaucoma (ORION 2.0)
The purpose of this study is to evaluate the safety and effectiveness of the OMNI® Surgical System in subjects who have undergone canaloplasty and trabeculotomy using OMNI® Surgical System without any concomitant surgery in…
- Trial name
- NCT04872348
- Testing
- OMNI® Surgical System
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Sight Sciences, Inc.
Primary Open Angle Glaucoma
Multicenter Post-Approval Study Of The Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery
The purpose of this study is to assess the long-term safety of the Glaukos® iStent® Trabecular Micro-Bypass Stent Model GTS100 in conjunction with cataract surgery vs.
- Trial name
- NCT01841450
- Testing
- iStent, Cataract surgery
- Where
- 14 sites in United States
- Volunteers
- 360 people
- Sponsor
- Glaukos Corporation
Open-Angle Glaucoma, Ocular Hypertension
Travoprost 3-Month Safety and Efficacy Study
The purpose of this study was to demonstrate that the intraocular pressure-lowering efficacy of Travoprost 0.003% is equivalent to TRAVATAN® in adult patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01453855
- Testing
- Travoprost ophthalmic solution, 0.003%, Travoprost ophthalmic solution, 0.004%
- Volunteers
- 1,099 people
- Sponsor
- Alcon Research
Primary Open-angle Glaucoma and Ocular Hypertension
DE-117 Spectrum 5 Study
Santen will evaluate the intraocular pressure (IOP) lowering effect and efficacy of DE-117 ophthalmic solution 0.002% in latanoprost low/non-responder subjects diagnosed with POAG or OHT
- Trial name
- NCT03697811
- Testing
- DE-117 Ophthalmic Solution
- Where
- 32 sites in United States
- Volunteers
- 107 people
- Sponsor
- Santen Inc.
Glaucoma, Open-Angle, Ocular Hypertension
Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution
This study will evaluate the safety, efficacy and dose-response of AGN-210669. This study will also compare AGN-210669 with bimatoprost ophthalmic solution (LUMIGAN®).
- Trial name
- NCT01001195
- Testing
- AGN-210669 ophthalmic solution, 0.1%, AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%
- Where
- United States
- Volunteers
- 165 people
- Sponsor
- Allergan
Open-Angle Glaucoma, Ocular Hypertension
Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension
The purpose of this study was to evaluate the safety and efficacy of Brinzolamide/Brimonidine in lowering intraocular pressure (IOP) relative to each of its individual active components in patients with open-angle glaucoma or…
- Trial name
- NCT01310777
- Testing
- Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide 1% ophthalmic suspension, Brimonidine tartrate 0.2% ophthalmic solution
- Volunteers
- 771 people
- Sponsor
- Alcon Research
Primary Open Angle Glaucoma (POAG)
Safety and Performance Study of the ARGOS-IO (Intraocular) System in Patients With Primary Open Angle Glaucoma (POAG)
The purpose of this study is to evaluate the safety and performance of the ARGOS-IO system in patients with POAG and indicated cataract surgery.
- Trial name
- NCT02434692
- Testing
- ARGOS-IO system
- Where
- 11 sites in Germany
- Volunteers
- 24 people
- Sponsor
- Implandata Ophthalmic Products GmbH
Glaucoma, Open-Angle, Ocular Hypertension
Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension
This study evaluated the ocular surface tolerability of the prostaglandin analogues bimatoprost ophthalmic solution 0.01% (Lumigan® 0.01%), travoprost ophthalmic solution 0.004% (Travatan Z®) and latanoprost ophthalmic solution…
- Trial name
- NCT01253902
- Testing
- bimatoprost ophthalmic solution 0.01%, travoprost ophthalmic solution 0.004%, latanoprost ophthalmic solution 0.005%
- Where
- 2 sites in United States, Canada
- Volunteers
- 164 people
- Sponsor
- Allergan
Glaucoma, Glaucoma, Open-Angle
Glaucoma Surgery Using the ViaLase Laser System
Prospective, single-center, multi-cohort clinical trial of ViaLase Laser for the reduction of IOP in patients with open angle glaucoma.
- Trial name
- NCT04949802
- Testing
- ViaLase Laser
- Where
- Hungary
- Volunteers
- 22 people
- Sponsor
- Vialase, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
Safety and Efficacy of a Glaucoma Drug Delivery System
The purpose of this study is to evaluate the ocular safety and efficacy of a glaucoma drug delivery system in open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00824720
- Testing
- High Dose Device, Low Dose Device
- Where
- 4 sites in United States
- Volunteers
- 55 people
- Sponsor
- Vistakon Pharmaceuticals
Open Angle Glaucoma, Ocular Hypertension
DuoTrav APS Versus XALACOM® in Ocular Surface Health
To demonstrate superiority of DuoTrav APS over XALACOM® in Ocular Surface Health in patients with open angle glaucoma or ocular hypertension.
- Trial name
- NCT00912054
- Testing
- DuoTrav APS, Xalacom
- Where
- Belgium
- Volunteers
- 240 people
- Sponsor
- Alcon Research
Open Angle Glaucoma
ELAZOP Switching Study in Korea
The purpose of this study is to assess the safety and efficacy of switching to ELAZOP from prior pharmacotherapy in patients with open-angled glaucoma.
- Trial name
- NCT01055366
- Testing
- Elazop (Azarga)
- Where
- 10 sites in South Korea
- Volunteers
- 96 people
- Sponsor
- Alcon Research
Open Angle Glaucoma, Ocular Hypertension
A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma
To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12.
- Trial name
- NCT00277498
- Testing
- Xalacom, Xalatan, Timolol
- Where
- 64 sites in United States
- Volunteers
- 528 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Open Angle Glaucoma, Ocular Hypertension
Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma
The objectives of this study are: To evaluate the efficacy of Phentolamine Mesylate to lower intra-ocular pressure (IOP) in the treatment of Open-Angle Glaucoma (OAG) and Ocular Hypertension (OHT).
- Trial name
- NCT03960866
- Testing
- Phentolamine Mesylate Ophthalmic Solution 1%
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Opus Genetics, Inc
Open Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension
The study is intended to test the effectiveness and safety of Netarsudil / Latanoprost 0.02% / 0.005% Ophthalmic Solution, relative to GANFORT® for lowering of intraocular pressure (IOP) in patients with elevated intraocular…
- Trial name
- NCT03284853
- Testing
- Netarsudil/Latanoprost 0.02%/0.005%, GANFORT®
- Where
- 68 sites in Austria, Belgium and 9 more
- Volunteers
- 436 people
- Sponsor
- Aerie Pharmaceuticals